These compounds and salts are described as cinasa JAK inhibitors. Some pharmaceutical ingredients are also provided, including JAK inhibitors and a carrier, adyuvante or an acceptable carrier on the drug, as well as methods to treat or reduce the disease or severity of the condition caused by the limited activity of the patient. 1. Claim 1: a formula compound (1),Or a pharmaceutically acceptable salt or stereoisomer, wherein: R1 is hydrogen, c1832131 asphalt；Alquenilo C83228331-832626；1. C 83228331 asphalt；-(c8332031) CN, - (lessor c833208331832323) or74919；-（C832031）R74919；-（C832031）832323 Sr74919；-(rent c8320)-(rent c8332031) ocf83323；-（C832031）CF 832323；-（C832031）832323；Nos.832222；-c（o）R74919；-c（o）Or74919；-c（o）NR74919；R74955；-（c）（o）R74959；-S（o）8321833183222；R74919；-(No. c83231-832391)； s (o) 8321833122； r74955；-S（o）8321833183222；NR7491；R74955；-(apartment c83320833183323) (heterosexual of 5-6 members) or - (apartment c83331832323) phenyl, wherein R1 may be replaced by one or more selected groups independent of halogen, apartment c83321c83183223；Oxo，CF832323，-Or7580y - (lessor c832031-83323y) or7580y - (lessor c833203183-83331) nr75803r74966；R74919 independent hydrogen, lease c833218331832626；3-10, 5-6, heterosexual, - C (o) r758080, - C (o) or758080；-C (o) No. 7580； - No. 74966； - No. 758080； - C (o) No. 74966；-S（O）832183318322；R758080；-No. 7580； (s (o) 832183318322；； r7496o-s (o) 832183383222；； No. 7580； r74966；a. Optionally replace any c833238331832626 and r74915-6 non bicycle with one or more r74977 process groups；R749595 independent hydrogen or c8332183331-83323；a. The asphalt can be replaced by one or more selection groups independent of halogen and oxo groups, or r75808 and r74966 hydrogen, heterocycle, c-cycloethane c833238331i8326 independent of 3-6 members；And rented c8332138323237a,1. Any 3-6 members of heterosexual, cyclo c8332331832626；e. Tar c833218331c833 and r758080 and r747996 can optionally be replaced by one or more selected groups independent of
